Company Summary - Reliance GeneMedix PLC (LSE:GMX)
1.75p
0.00p
Pharmaceuticals & BiotechnologyMarket cap: £2.725m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development & manufacture biopharmaceuticals, including biosimilars, which are a generic version of innovative therapeutic proteins
| Financials - Interim (23/12/2008) | ||
|---|---|---|
| Turnover | £m | 0.19 |
| Pre-tax Profit | £m | -1.62 |
| EPS | p | -1.03 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Dr. Ramesh Mashelkar | Chairman |
| Vinay Ranade | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
Epidermal Growth Factor; Erythropoietin; Granulocyte Colony Stimulating Factor; Human Growth Hormone; Interferon alfa...
Subsidiaries
Shanghai GeneMedix Biotechnology Company Ltd
Free Annual Reports
The PrecisionIR Group Annual Reports Service provides you with quick access to annual reports and other information on selected companies.
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Reliance GeneMedix 1H Pretax Los... | 23/12/2008 |
| Half Yearly Report | 23/12/2008 |
| Directorate Change | 11/12/2008 |